Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

9.110 -0.040 (-0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,468,515
Open 9.180
Bid (Size) 9.120 (10)
Ask (Size) 9.200 (3)
Prev. Close 9.150
Today's Range 8.890 - 9.348
52wk Range 8.650 - 17.82
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Look Ahead: Evolus's Earnings Forecast
 
Via Benzinga
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
From Evolus
Via Business Wire

Performance

YTD
-18.0%
-18.0%
1 Month
-0.3%
-0.3%
3 Month
-24.1%
-24.1%
6 Month
-29.8%
-29.8%
1 Year
-31.6%
-31.6%

More News

Read More
Evolus to Report Second Quarter Financial Results on August 5, 2025
From Evolus
Via Business Wire
Earnings Scheduled For May 7, 2025
Via Benzinga
Assessing Evolus: Insights From 6 Financial Analysts
Via Benzinga
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolysse™ Recognized in 2025 Shape Skin Awards
From Evolus
Via Business Wire
Evolus Announces Departure of its Chief Financial Officer
From Evolus
Via Business Wire
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
What Analysts Are Saying About Evolus Stock
Via Benzinga
Evolus Reports First Quarter 2025 Results
From Evolus
Via Business Wire
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
From Evolus
Via Business Wire
Evolus to Report First Quarter Financial Results on May 7, 2025
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Evolus Announces Commercial Launch of Evolysse™
From Evolus
Via Business Wire
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
Breaking Down Evolus: 8 Analysts Share Their Views
Via Benzinga
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
Via The Motley Fool
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
From Evolus
Via Business Wire

Frequently Asked Questions

Is Evolus, Inc. - Common Stock publicly traded?
Yes, Evolus, Inc. - Common Stock is publicly traded.
What exchange does Evolus, Inc. - Common Stock trade on?
Evolus, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Evolus, Inc. - Common Stock?
The ticker symbol for Evolus, Inc. - Common Stock is EOLS on the Nasdaq Stock Market
What is the current price of Evolus, Inc. - Common Stock?
The current price of Evolus, Inc. - Common Stock is 9.110
When was Evolus, Inc. - Common Stock last traded?
The last trade of Evolus, Inc. - Common Stock was at 08/04/25 04:00 PM ET
What is the market capitalization of Evolus, Inc. - Common Stock?
The market capitalization of Evolus, Inc. - Common Stock is 497.19M
How many shares of Evolus, Inc. - Common Stock are outstanding?
Evolus, Inc. - Common Stock has 497M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.